Posted by Michael Wonder on 15 Nov 2023
Chemomab Therapeutics receives FDA fast track designation for CM-101 for the treatment of primary sclerosing cholangitis
15 November 2023 - CM-101's unique dual anti-fibrotic and anti-inflammatory activity has disease modifying potential in this poorly treated condition.
Chemomab Therapeutics today announced that the US FDA has granted CM-101 fast track designation for the treatment in adult patients of primary sclerosing cholangitis, a fibrotic liver disease that can result in liver transplant, cancer and early death.
